ANI Free Cash Flow Per Share from 2010 to 2025

ANIP Stock  USD 68.36  1.19  1.77%   
ANI Pharmaceuticals Free Cash Flow Per Share yearly trend continues to be relatively stable with very little volatility. Free Cash Flow Per Share is likely to grow to 3.48 this year. Free Cash Flow Per Share is the amount of cash ANI Pharmaceuticals generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share. View All Fundamentals
 
Free Cash Flow Per Share  
First Reported
2010-12-31
Previous Quarter
3.31385237
Current Value
3.48
Quarterly Volatility
9.69289346
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 71.1 M, Interest Expense of 18.5 M or Selling General Administrative of 262.1 M, as well as many indicators such as Price To Sales Ratio of 1.65, Dividend Yield of 0.0012 or PTB Ratio of 2.37. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of ANI Pharmaceuticals Correlation against competitors.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Latest ANI Pharmaceuticals' Free Cash Flow Per Share Growth Pattern

Below is the plot of the Free Cash Flow Per Share of ANI Pharmaceuticals over the last few years. It is the amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share. ANI Pharmaceuticals' Free Cash Flow Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Free Cash Flow Per Share10 Years Trend
Slightly volatile
   Free Cash Flow Per Share   
       Timeline  

ANI Free Cash Flow Per Share Regression Statistics

Arithmetic Mean(4.26)
Coefficient Of Variation(227.46)
Mean Deviation6.63
Median(1.36)
Standard Deviation9.69
Sample Variance93.95
Range38.2815
R-Value0.70
Mean Square Error51.26
R-Squared0.49
Significance0
Slope1.43
Total Sum of Squares1,409

ANI Free Cash Flow Per Share History

2025 3.48
2024 3.31
2023 5.58
2022 -2.93
2021 -1.61
2020 -4.43
2019 1.53

About ANI Pharmaceuticals Financial Statements

ANI Pharmaceuticals shareholders use historical fundamental indicators, such as Free Cash Flow Per Share, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Free Cash Flow Per Share 3.31  3.48 

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.